By reducing appetite, stabilizing blood sugar, and supporting healthy eating habits, it helps patients achieve meaningful, long-term results
That dual mechanism, reduced input plus increased output, explains the dramatic differences in clinical trial results
Notably, surgical patients achieved greater absolute weight loss yet the GLP-1 cohort demonstrated a comparatively lower incidence of obesity-related cancers
Retatrutide has developed one of the most rapidly growing pre-clinical research profiles of any metabolic peptide currently in active study: Pre-clinical metabolic research in obese animal models has reported body weight and fat mass reductions with Retatrutide that exceed those observed with dual-receptor compounds including Tirzepatide at comparable doses and suggesting that the addition of glucagon receptor engagement to combined GLP-1/GIP agonism produces meaningfully greater metabolic effects in experimental settings
We set up very realistic expectations, and then we help a person with diabetes to get where they want to get." Eichorst primarily works with patients taking GLP-1s for diabetes management, not obesity care
10.3390/ijms24054901
